an individual who meets any of the following criteria will be excluded from participation in this study: 1. evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury) 2. known active inflammatory bowel disease 3. known active, untreated diverticulitis 4. known untreated bacteremia 5. pregnancy. (the protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis). 6. known hypersensitivity to the clazakizumab

an individual who meets any of the following criteria will be excluded from participation in this study: 1. evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury) 2. known active inflammatory bowel disease 3. known active, untreated diverticulitis 4. known untreated bacteremia 5. pregnancy. (the protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis). 6. known hypersensitivity to the clazakizumab

an individual who meets any of the following criteria will be excluded from participation in this study: evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury) known active inflammatory bowel disease known active, untreated diverticulitis known untreated bacteremia pregnancy. (the protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis). known hypersensitivity to the clazakizumab

an individual who meets any of the following criteria will be excluded from participation in this study: evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury) known active inflammatory bowel disease known active, untreated diverticulitis known untreated bacteremia pregnancy. (the protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis). known hypersensitivity to the clazakizumab

an individual who meets any of the following criteria will be excluded from participation in this study: 1. evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury) 2. known active inflammatory bowel disease 3. known active, untreated diverticulitis 4. known untreated bacteremia 5. pregnancy. (the protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis). 6. known hypersensitivity to the clazakizumab

an individual who meets any of the following criteria will be excluded from participation in this study: 1. evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury) 2. known active inflammatory bowel disease 3. known active, untreated diverticulitis 4. known untreated bacteremia 5. pregnancy. (the protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis). 6. known hypersensitivity to the clazakizumab